{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:00:44Z","timestamp":1792814444991,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The research and open access are supported by PharmaEssentia."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06480-1","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:52:32Z","timestamp":1752141152000},"page":"3669-3679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1007","volume":"104","author":[{"given":"Brandi N.","family":"Reeves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Abu-Zeinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Shatzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"12","key":"6480_CR1","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95(12):1599\u20131613. https:\/\/doi.org\/10.1002\/ajh.26008","journal-title":"Am J Hematol"},{"key":"6480_CR2","doi-asserted-by":"publisher","unstructured":"Barbui T, Vannucchi AM, De Stefano V et al (2023) Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid 2(6). https:\/\/doi.org\/10.1056\/EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335"},{"issue":"2","key":"6480_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-023-05577-9","volume":"103","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, De Stefano V et al (2024) Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. Ann Hematol 103(2):437\u2013442. https:\/\/doi.org\/10.1007\/s00277-023-05577-9","journal-title":"Ann Hematol"},{"issue":"19","key":"6480_CR4","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT et al (2022) A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 139(19):2931\u20132941. https:\/\/doi.org\/10.1182\/blood.2021012743","journal-title":"Blood"},{"issue":"12","key":"6480_CR5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1080\/14740338.2021.1945032","volume":"20","author":"M Griesshammer","year":"2021","unstructured":"Griesshammer M, Kai W, Parvis S, Frank S, D\u00f6hner K (2021) A review of hydroxyurea-related cutaneous adverse events. Exp Opin Drug Saf 20(12):1515\u20131521. https:\/\/doi.org\/10.1080\/14740338.2021.1945032","journal-title":"Exp Opin Drug Saf"},{"issue":"10","key":"6480_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2023) Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia 37(10):2129\u20132132. https:\/\/doi.org\/10.1038\/s41375-023-02008-6","journal-title":"Leukemia"},{"issue":"3","key":"6480_CR7","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196\u2013e208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4","journal-title":"Lancet Haematol"},{"key":"6480_CR8","unstructured":"U.S. Food and Drug Administration. FDA news release: FDA approves treatment for rare blood disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-blood-disease. Accessed 21December2021"},{"issue":"1\u20132","key":"6480_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh1245","volume":"13","author":"SS Suo","year":"2024","unstructured":"Suo SS, Fu RF, Qin A et al (2024) Effective management of polycythemia vera with ropeginterferon alfa-2b treatment. J Hematol 13(1\u20132):12\u201322. https:\/\/doi.org\/10.14740\/jh1245","journal-title":"J Hematol"},{"issue":"6","key":"6480_CR10","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1111\/bjh.19846","volume":"205","author":"S Suo","year":"2024","unstructured":"Suo S, Fu RF, Qin A et al (2024) Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b. Br J Haematol 205(6):2510\u20132514. https:\/\/doi.org\/10.1111\/bjh.19846","journal-title":"Br J Haematol"},{"key":"6480_CR11","doi-asserted-by":"publisher","first-page":"1455979","DOI":"10.3389\/fphar.2024.1455979","volume":"15","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Liao J et al (2024) Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b. Front Pharmacol 15:1455979. https:\/\/doi.org\/10.3389\/fphar.2024.1455979","journal-title":"Front Pharmacol"},{"issue":"1","key":"6480_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A et al (2023) A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol 12(1):55. https:\/\/doi.org\/10.1186\/s40164-023-00415-0","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"6480_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A et al (2022) Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol 116(2):215\u2013227. https:\/\/doi.org\/10.1007\/s12185-022-03341-9","journal-title":"Int J Hematol"},{"issue":"1","key":"6480_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s44276-024-00076-4","volume":"2","author":"K Kirito","year":"2024","unstructured":"Kirito K, Qin A, Suo S et al (2024) Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia. BJC Rep 2(1):51. https:\/\/doi.org\/10.1038\/s44276-024-00076-4","journal-title":"BJC Rep"},{"key":"6480_CR15","doi-asserted-by":"publisher","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T et al (20221) Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia 35(9):2592\u20132601. https:\/\/doi.org\/10.1038\/s41375-021-01183-8","DOI":"10.1038\/s41375-021-01183-8"},{"key":"6480_CR16","doi-asserted-by":"publisher","first-page":"1173467","DOI":"10.3389\/fonc.2023.1173467","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A (2023) An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol 13:1173467. https:\/\/doi.org\/10.3389\/fonc.2023.1173467","journal-title":"Front Oncol"},{"key":"6480_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1089\/jir.1997.17.355","volume":"17","author":"X-Q Qin","year":"1997","unstructured":"Qin X-Q, Runkel L, Deck C, DeDios C, Barsoum J (1997) Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interf Cytokine Res 17:355\u2013367. https:\/\/doi.org\/10.1089\/jir.1997.17.355","journal-title":"J Interf Cytokine Res"},{"key":"6480_CR18","unstructured":"National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, version 1.2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477"},{"issue":"12","key":"6480_CR19","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ajh.25270","volume":"93","author":"N Szuber","year":"2018","unstructured":"Szuber N, Vallapureddy RR, Penna D et al (2018) Myeloproliferative neoplasms in the young: Mayo clinic experience with 361 patients age 40 years or younger. Am J Hematol 93(12):1474\u20131484. https:\/\/doi.org\/10.1002\/ajh.25270","journal-title":"Am J Hematol"},{"key":"6480_CR20","unstructured":"U.S. Food and Drug Administration Department of Health and Human Services. Title 21 (21CFR) 312.32, (2004)"},{"key":"6480_CR21","doi-asserted-by":"publisher","unstructured":"Anand K, Sahu G, Burns E et al (2020) Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open 5(4). https:\/\/doi.org\/10.1136\/esmoopen-2020-000866","DOI":"10.1136\/esmoopen-2020-000866"},{"issue":"6","key":"6480_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1592\/phco.26.6.748","volume":"26","author":"A Szarfman","year":"2006","unstructured":"Szarfman A, Tonning JM, Levine JG, Doraiswamy PM (2006) Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacother 26(6):748\u2013758. https:\/\/doi.org\/10.1592\/phco.26.6.748","journal-title":"Pharmacother"},{"issue":"5","key":"6480_CR23","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/bcp.15176","volume":"88","author":"YW Huang","year":"2022","unstructured":"Huang YW, Qin A, Fang J et al (2022) Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharmacol 88(5):2396\u20132407. https:\/\/doi.org\/10.1111\/bcp.15176","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"6480_CR24","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/bcp.16043","volume":"90","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Li Y et al (2024) Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. Br J Clin Pharmacol 90(6):1493\u20131502. https:\/\/doi.org\/10.1111\/bcp.16043","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"6480_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A (2021) Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig 41(4):391\u2013404. https:\/\/doi.org\/10.1007\/s40261-021-01026-5","journal-title":"Clin Drug Investig"},{"issue":"Supplement 1","key":"6480_CR26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2023-173127","volume":"142","author":"TA Knudsen","year":"2023","unstructured":"Knudsen TA, Hansen DL, Ocias LF et al (2023) Final analysis of the Daliah trial: A randomized phase III trial of interferon-\u03b1 versus hydroxyurea in patients with MPN. Blood 142(Supplement 1):746\u2013746. https:\/\/doi.org\/10.1182\/blood-2023-173127","journal-title":"Blood"},{"issue":"6","key":"6480_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12072-020-10098-y","volume":"14","author":"YW Huang","year":"2020","unstructured":"Huang YW, Hsu CW, Lu SN, Yu ML, Su CW, Su WW, Chien RN, Hsu CS, Hsu SJ, Lai HC, Qin A, Tseng KC, Chen PJ (2020) Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatol Int 14(6):997\u20131008. https:\/\/doi.org\/10.1007\/s12072-020-10098-y","journal-title":"Hepatol Int"},{"key":"6480_CR28","doi-asserted-by":"publisher","first-page":"1109866","DOI":"10.3389\/fonc.2023.1109866","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J (2023) An alternative dosing strategy for ropeginterferon alfa-2b May help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol 13:1109866. https:\/\/doi.org\/10.3389\/fonc.2023.1109866","journal-title":"Front Oncol"},{"issue":"23","key":"6480_CR29","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","volume":"343","author":"EJ Heathcote","year":"2000","unstructured":"Heathcote EJ, Shiffman ML, Cooksley WGE et al (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343(23):1673\u20131680. https:\/\/doi.org\/10.1056\/NEJM200012073432302","journal-title":"N Engl J Med"},{"issue":"5","key":"6480_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"issue":"5","key":"6480_CR31","doi-asserted-by":"publisher","first-page":"e13043","DOI":"10.1111\/dth.13043","volume":"32","author":"C Cantisani","year":"2019","unstructured":"Cantisani C, Kiss N, Naqeshbandi AF et al (2019) Nonmelanoma skin cancer associated with hydroxyurea treatment: overview of the literature and our own experience. Dermatol Ther 32(5):e13043. https:\/\/doi.org\/10.1111\/dth.13043","journal-title":"Dermatol Ther"},{"issue":"2","key":"6480_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","volume":"86","author":"JQ Lin","year":"2022","unstructured":"Lin JQ, Li SQ, Li S et al (2022) A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol 86(2):339\u2013344. https:\/\/doi.org\/10.1016\/j.jaad.2021.10.004","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"6480_CR33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"6480_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35411","author":"SY Yoon","year":"2025","unstructured":"Yoon SY, Yoon S-S, Yang D-H et al (2025) Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.35411","journal-title":"Int J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06480-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T16:02:38Z","timestamp":1754668958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06480-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6480"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06480-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Brandi Reeves: has received consulting fees from PharmaEssentia, CTI BioPharma, and Incyte. Lucia Masarova: advisory board participation with Cogent, GSK, MorphoSys, and PharmaEssentia. Ghaith Abu-Zeinah: research support provided to the institution from PharmaEssentia. Anthony M Hunter: has received honoraria\/consulting fees from GSK, Cogent Biosciences, PharmaEssentia, Blueprint Medicines, CTI Biopharma (now Sobi) and Incyte; declares research funding from Incyte, Cogent Biosciences, Ascentage Pharma, Blueprint Medicines, Syntrix Biosystems, Novartis, and PharmaEssentia. Joseph Shatzel: No relevant Conflicts. Albert Qin: serves as chief medical officer of PharmaEssentia. Chang Ho Yoon: consultant for PharmaEssentia. Ling-Yu Cai: employee of Vizuro LLC which has provided data analysis for PharmaEssentia Yu-Feng Wei: co-founder and CEO of Vizuro LLC which has provided data analysis for PharmaEssentia. R Mesa: consultant (Honoraria) over past 3 years: Abbvie, Blueprint, BMS, CTI, Genentech, Geron, GSK, Incyte, Novartis, Sierra, Sierra Oncology, Telios; Research Support: Abbvie, Blueprint, BMS, CTI, Genentech, Incyte, Morphosys, Sierra.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}